{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:33:22Z","timestamp":1782455602597,"version":"3.54.5"},"reference-count":170,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>It is now well known that the bone marrow (BM) cell niche contributes to leukemogenesis, but emerging data support the role of the complex crosstalk between AML cells and the BM microenvironment to induce a permissive immune setting that protects leukemic stem cells (LSCs) from therapy-induced death, thus favoring disease persistence and eventual relapse. The identification of potential immune targets on AML cells and the modulation of the BM environment could lead to enhanced anti-leukemic effects of drugs, immune system reactivation, and the restoration of AML surveillance. Potential targets and effectors of this immune-based therapy could be monoclonal antibodies directed against LSC antigens such as CD33, CD123, and CLL-1 (either as direct targets or via several bispecific T-cell engagers), immune checkpoint inhibitors acting on different co-inhibitory axes (alone or in combination with conventional AML drugs), and novel cellular therapies such as chimeric antigen receptor (CAR) T-cells designed against AML-specific antigens. Though dozens of clinical trials, mostly in phases I and II, are ongoing worldwide, results have still been negatively affected by difficulties in the identification of the optimal targets on LSCs.<\/jats:p>","DOI":"10.3390\/cancers15010253","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T03:00:59Z","timestamp":1672628459000},"page":"253","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Present and Future Role of Immune Targets in Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1663-4468","authenticated-orcid":false,"given":"Daniela","family":"Damiani","sequence":"first","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, Udine Hospital, 33100 Udine, Italy"},{"name":"Department of Medicine (DAME), University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-2621","authenticated-orcid":false,"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation, Udine Hospital, 33100 Udine, Italy"},{"name":"Department of Medicine (DAME), University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ijc.33908","article-title":"Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough?","volume":"150","author":"Ganesan","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","article-title":"Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia","volume":"19","author":"Goardon","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.stem.2019.07.001","article-title":"Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia","volume":"25","author":"McKenzie","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Hong","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17ra19","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1182\/bloodadvances.2020001802","article-title":"CD200 expression marks leukemia stem cells in human AML","volume":"4","author":"Ho","year":"2020","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2015-11-683649","article-title":"GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo","volume":"127","author":"Pabst","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.leukres.2014.03.007","article-title":"N-Cadherin and Tie2 positive CD34(+)CD38(-)CD123(+) leukemic stem cell populations can develop acute myeloid leukemia more effectively in NOD\/SCID mice","volume":"38","author":"Qiu","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"Kelder","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/stem.2897","article-title":"c-MPL Is a Candidate Surface Marker and Confers Self-Renewal, Quiescence, Chemotherapy Resistance, and Leukemia Initiation Potential in Leukemia Stem Cells","volume":"36","author":"Li","year":"2018","journal-title":"Stem Cells"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-019-0522-9","article-title":"Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia","volume":"34","author":"Wang","year":"2020","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13398","article-title":"An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: Blood frequency of CD34+ CD38 low blasts","volume":"170","author":"Khan","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/leu.2017.259","article-title":"Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41420-022-01193-0","article-title":"The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting","volume":"8","author":"Chen","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1172\/JCI133187","article-title":"Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia","volume":"130","author":"Waclawiczek","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e23850","DOI":"10.4161\/onci.23850","article-title":"A \u201cvicious cycle\u201d of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL?","volume":"2","author":"Schmiedel","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e90036","DOI":"10.1172\/jci.insight.90036","article-title":"AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth","volume":"2","author":"Battula","year":"2017","journal-title":"JCI Insight"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2011-04-348151","article-title":"Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia","volume":"119","author":"Frisch","year":"2012","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0301-472X(01)00612-9","article-title":"Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5)","volume":"29","author":"Garrido","year":"2001","journal-title":"Exp. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3727\/096504016X14634208143021","article-title":"Induction of Multidrug Resistance of Acute Myeloid Leukemia Cells by Cocultured Stromal Cells via Upregulation of the PI3K\/Akt Signaling Pathway","volume":"24","author":"Chen","year":"2016","journal-title":"Oncol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2141.1993.tb03168.x","article-title":"Acute myeloid leukaemia blast cells bind to human endothelium in vitro utilizing E-selectin and vascular cell adhesion molecule-1 (VCAM-1)","volume":"85","author":"Cavenagh","year":"1993","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.V97.7.2121","article-title":"Endothelial cell activation by myeloblasts: Molecular mechanisms of leukostasis and leukemic cell dissemination","volume":"97","author":"Stucki","year":"2001","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/carcin\/bgs386","article-title":"Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch\/Dll4 pathway","volume":"34","author":"Zhang","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.V89.6.1870","article-title":"Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia","volume":"89","author":"Fiedler","year":"1997","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.it.2011.03.009","article-title":"Control of hematopoietic stem cells by the bone marrow stromal niche: The role of reticular cells","volume":"32","author":"Nagasawa","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ar.1091860204","article-title":"The hematopoietic microenvironment of the bone marrow: An ultrastructural study of the stroma in rats","volume":"186","author":"Weiss","year":"1976","journal-title":"Anat. Rec."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.immuni.2004.05.001","article-title":"Cellular niches controlling B lymphocyte behavior within bone marrow during development","volume":"20","author":"Tokoyoda","year":"2004","journal-title":"Immunity"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2007-04-084210","article-title":"Development of plasmacytoid dendritic cells in bone marrow stromal cell niches requires CXCL12-CXCR4 chemokine signaling","volume":"110","author":"Kohara","year":"2007","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2010-04-277897","article-title":"CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice","volume":"117","author":"Noda","year":"2011","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.7150\/thno.5150","article-title":"Role of CXCR4 in the pathogenesis of acute myeloid leukemia","volume":"3","author":"Peled","year":"2013","journal-title":"Theranostics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/10245332.2018.1486064","article-title":"Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia","volume":"23","author":"Wang","year":"2018","journal-title":"Hematology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","article-title":"Bone marrow niches in haematological malignancies","volume":"20","author":"Bonnet","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cmet.2020.09.001","article-title":"Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy","volume":"32","author":"Forte","year":"2020","journal-title":"Cell Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ncb3570","article-title":"Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF","volume":"19","author":"Zhou","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood-2016-08-734798","article-title":"Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment","volume":"129","author":"Shafat","year":"2017","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e20190589","DOI":"10.1084\/jem.20190589","article-title":"Mapping and targeting of the leukemic microenvironment","volume":"217","author":"Witkowski","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1158\/1541-7786.MCR-17-0338","article-title":"Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin","volume":"15","author":"Sheng","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","article-title":"Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia","volume":"102","author":"Sun","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e1469594","DOI":"10.1080\/2162402X.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1158\/1078-0432.CCR-11-2939","article-title":"Molecular pathways: Tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment","volume":"18","author":"Lu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.reth.2021.02.006","article-title":"Immune evasion by cancer stem cells","volume":"17","author":"Tsuchiya","year":"2021","journal-title":"Regen. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","article-title":"MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1062208","DOI":"10.1080\/2162402X.2015.1062208","article-title":"Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome","volume":"5","author":"Kittang","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"166268","DOI":"10.1016\/j.bbadis.2021.166268","article-title":"GPX1-associated prognostic signature predicts poor survival in patients with acute myeloid leukemia and involves in immunosuppression","volume":"1868","author":"Zhang","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000500315","article-title":"The Role of Tumor-Associated Macrophages in Leukemia","volume":"143","author":"Li","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kuek, V., Hughes, A.M., Kotecha, R.S., and Cheung, L.C. (2021). Therapeutic Targeting of the Leukaemia Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136888"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4049\/jimmunol.174.3.1269","article-title":"Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells","volume":"174","author":"Becker","year":"2005","journal-title":"J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nm914","article-title":"Bone marrow as a priming site for T-cell responses to blood-borne antigen","volume":"9","author":"Feuerer","year":"2003","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fimmu.2016.00184","article-title":"A T Cell View of the Bone Marrow","volume":"7","author":"Bonomo","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood.V84.8.2436.2436","article-title":"Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells","volume":"84","author":"Kaufman","year":"1994","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2006-04-016410","article-title":"Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse","volume":"109","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.4049\/jimmunol.0802212","article-title":"Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia","volume":"182","author":"Zheng","year":"2009","journal-title":"J. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.V90.5.2103","article-title":"Bone marrow contains virus-specific cytotoxic T lymphocytes","volume":"90","author":"Slifka","year":"1997","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.bmt.1704582","article-title":"Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation","volume":"34","author":"Haraguchi","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clim.2004.08.017","article-title":"Characterization of NKR+ T-cell subsets in human bone marrow: Implications for immunosurveillance of neoplasia","volume":"114","author":"Dean","year":"2005","journal-title":"Clin. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.4049\/jimmunol.169.8.4213","article-title":"The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity","volume":"169","author":"Underhill","year":"2002","journal-title":"J. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: How AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1158\/1078-0432.CCR-19-3003","article-title":"Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia","volume":"26","author":"Tang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-021-00265-0","article-title":"Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment","volume":"9","author":"Guo","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e159579","DOI":"10.1172\/JCI159579","article-title":"Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia","volume":"132","author":"Rutella","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/14728222.2014.909413","article-title":"The role of CD33 as therapeutic target in acute myeloid leukemia","volume":"18","author":"Walter","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-17-1077","article-title":"IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML","volume":"17","author":"Kovtun","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_83","first-page":"98","article-title":"CD123 (interleukin 3 receptor alpha chain)","volume":"15","author":"Moretti","year":"2001","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.1074\/jbc.M313127200","article-title":"Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes","volume":"279","author":"Marshall","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting CLL-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/1078-0432.CCR-18-0333","article-title":"An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia","volume":"25","author":"Zheng","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","article-title":"CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia","volume":"2","author":"Jiang","year":"2018","journal-title":"Blood Adv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.4049\/jimmunol.180.11.7358","article-title":"Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte\/macrophage progenitor stages to maintain cell survival","volume":"180","author":"Kikushige","year":"2008","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13277-010-0042-8","article-title":"Radiation-induced cell death mechanisms","volume":"31","author":"Eriksson","year":"2010","journal-title":"Tumour Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bjh.15078","article-title":"Immune checkpoint molecules in acute myeloid leukaemia: Managing the double-edged sword","volume":"181","author":"Hobo","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1158\/1078-0432.CCR-17-3016","article-title":"Novel Approaches to Acute Myeloid Leukemia Immunotherapy","volume":"24","author":"Gill","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: From mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune checkpoint inhibitors in cancer therapy: A focus on T-regulatory cells","volume":"96","author":"Elkord","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3389\/fimmu.2018.02041","article-title":"Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells","volume":"9","author":"Kim","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","article-title":"The emerging role of immune checkpoint based approaches in AML and MDS","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for Patients with Relapse after Allogeneic Transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: A systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/08880018.2017.1383542","article-title":"Checkpoint inhibition in pediatric hematologic malignancies","volume":"34","author":"Davis","year":"2017","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Giannopoulos, K. (2019). Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020236"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.1200\/JCO.2018.36.15_suppl.7014","article-title":"Nivolumab (NIVO) Maintenance (mainT) in High-Risk (HR) Acute Myeloid Leukemia (AML) Patients","volume":"34","author":"Kadia","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"7026","DOI":"10.1200\/JCO.2017.35.15_suppl.7026","article-title":"Phase IB\/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML","volume":"36","author":"Daver","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V130.Suppl_1.815.815","article-title":"Phase 2 study of combination of cytarabine, idarubicin, and nivolumab for initial therapy of patients with newly diagnosed acute myeloid leukemia","volume":"130","author":"Ravandi","year":"2017","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4049\/jimmunol.1400557","article-title":"Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion","volume":"193","author":"Ferris","year":"2014","journal-title":"J. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2017.00760","article-title":"NK Cell Exhaustion","volume":"8","author":"Bi","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1158\/1078-0432.CCR-16-2848","article-title":"Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma","volume":"23","author":"Giraldo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14737140.2021.1865814","article-title":"TIM-3 pathway dysregulation and targeting in cancer","volume":"21","author":"Zeidan","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"30212","DOI":"10.18632\/oncotarget.4901","article-title":"Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors","volume":"6","author":"Damiani","year":"2015","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.leu.2404559","article-title":"CD200 as a prognostic factor in acute myeloid leukaemia","volume":"21","author":"Tonks","year":"2007","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/leu.2012.75","article-title":"Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells","volume":"26","author":"Coles","year":"2012","journal-title":"Leukemia"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/leu.2015.62","article-title":"The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: Identification of a new immunotherapeutic synapse","volume":"29","author":"Coles","year":"2015","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e150750","DOI":"10.1172\/JCI150750","article-title":"CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis","volume":"132","author":"Morgan","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjh.17125","article-title":"Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo","volume":"193","author":"Rastogi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri1859","article-title":"The SIRP family of receptors and immune regulation","volume":"6","author":"Barclay","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRPalphaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.4238\/2015.May.25.15","article-title":"Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro","volume":"14","author":"Wang","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2022-170188","article-title":"Phase I\/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older\/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed\/Refractory (R\/R) AML","volume":"140","author":"Daver","year":"2022","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood-2021-146547","article-title":"Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1\/2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)","volume":"138","author":"Erba","year":"2021","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: An emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2011-02-337691","article-title":"DARTs take aim at BiTEs","volume":"117","author":"Rader","year":"2011","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Allen, C., Zeidan, A.M., and Bewersdorf, J.P. (2021). BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?. Life, 11.","DOI":"10.3390\/life11060465"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","article-title":"CD33\/CD3-bispecific T-cell engaging (BiTE(R)) antibody construct targets monocytic AML myeloid-derived suppressor cells","volume":"6","author":"Jitschin","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","article-title":"Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML","volume":"123","author":"Laszlo","year":"2014","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","author":"Ravandi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2019-129042","article-title":"Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33\/CD3 T-Cell Engager, in Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML)","volume":"134","author":"Westervelt","year":"2018","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.molimm.2011.09.019","article-title":"Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module","volume":"49","author":"Stamova","year":"2011","journal-title":"Mol. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood.V124.21.2316.2316","article-title":"Immunotherapy with Long-Lived Anti-CD123 \u00d7 Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia","volume":"124","author":"Chu","year":"2014","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-134746","article-title":"Responses in Relapsed\/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 \u00d7 CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study","volume":"136","author":"Ravandi","year":"2020","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/1538-7445.AM2019-LB-199","article-title":"APVO436, a bispecific anti-CD123 \u00d7 anti-CD3 ADAPTIRTM molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques","volume":"13","author":"Comeau","year":"2019","journal-title":"Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-141619","article-title":"Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 \u00d7 Anti-CD3 Bispecific Molecule, in Relapsed\/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"136","author":"Watts","year":"2020","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1182\/blood-2019-125966","article-title":"A Phase 1 Study of Flotetuzumab, a CD123 \u00d7 CD3 DART\u00ae Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"289ra282","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e1472195","DOI":"10.1080\/2162402X.2018.1472195","article-title":"Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells","volume":"7","author":"Braciak","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2022-163104","article-title":"Spatially Confined T-Cell Mediated Anti-AML Tumor Immunity By Dual Recognition Antibodies (CD123\/CD200)","volume":"140","author":"Dickopf","year":"2022","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V126.23.325.325","article-title":"Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AM","volume":"126","author":"Doornbos","year":"2015","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/14712598.2019.1623200","article-title":"MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis","volume":"19","author":"Hangalapura","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1182\/blood-2018-99-117150","article-title":"CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia","volume":"132","author":"Arvindam","year":"2018","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-19-1093","article-title":"Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia","volume":"19","author":"Brauchle","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1182\/blood-2022-162201","article-title":"Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL","volume":"140","author":"Sammicheli","year":"2022","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: Current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_159","unstructured":"Liu, F., Zhang, H., Sun, L., Li, Y., Shan, Z., He, G., Yi, H., Wada, M., Pinz, K., and Chen, K. (2020, January 11\u201321). First in human CLL1-CD33 compund (CCAR) T Cell Therapy in relapsed and refractory Acute Myeloid Leukemia. Proceedings of the European Hematology Association Congress, Online. Abstract S149."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: A novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2021-152692","article-title":"A Phase 1\/1b safety study of Prgn-3006 Ultracar-T\u2122 in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndrome","volume":"138","author":"Sallman","year":"2021","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2021-147321","article-title":"Multi- modal targeting of FLT3 with chimeric antigen receptor T cell immuno- therapy and tyrosine kinase inhibition in high-risk pediatric leukemias","volume":"138","author":"Niswander","year":"2021","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2021-148649","article-title":"Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies","volume":"138","author":"Choi","year":"2021","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2021-154201","article-title":"FLT3 OR CD33 NOT EMCN logic gated CAR-NK cell therapy (SENTI- =202) for precise targeting of AML","volume":"138","author":"Garrison","year":"2021","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1182\/blood-2021-147244","article-title":"Tc buster transposon engineered CLL-1 CAR-NK cells efficiently target acute myeloid leukemia","volume":"138","author":"Gurney","year":"2021","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1182\/blood-2022-169758","article-title":"CRISPR\/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML","volume":"140","author":"Albinger","year":"2022","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2022-168877","article-title":"Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed\/Refractory AML","volume":"140","author":"Ehninger","year":"2022","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R\/R) CD123+ Acute Myeloid Leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1182\/blood-2022-168719","article-title":"Single and Combinational Multiplex Base-Edited \u2018Universal\u2019 CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML","volume":"140","author":"Kloos","year":"2022","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/253\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:48:36Z","timestamp":1760147316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":170,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15010253"],"URL":"https:\/\/doi.org\/10.3390\/cancers15010253","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}